ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
10.73
+0.39 (3.77%)
At close: Oct 15, 2026, 4:00 PM EDT
10.66
-0.07 (-0.65%)
After-hours: Oct 15, 2026, 7:30 PM EDT
ADMA Biologics Employees
As of December 31, 2025, ADMA Biologics had 647 total employees, including 640 full-time and 7 part-time employees. The number of employees decreased by 38 or -5.55% compared to the previous year. That makes ADMA Biologics the 18,100th largest employer in the world and 2,489th in the United States.
Employees
647
Change (1Y)
-38
Growth (1Y)
-5.55%
Revenue / Employee
$791,770
Profits / Employee
$261,141
Market Cap
2.40B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 647 | -38 | -5.55% | 640 | 7 |
| Dec 31, 2024 | 685 | 61 | 9.78% | 677 | 8 |
| Dec 31, 2023 | 624 | 7 | 1.13% | 624 | 0 |
| Dec 31, 2022 | 617 | 90 | 17.08% | 617 | 0 |
| Dec 31, 2021 | 527 | 120 | 29.48% | 527 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Beam Therapeutics | 540 |
| Nurix Therapeutics | 317 |
| Harmony Biosciences Holdings | 293 |
| Celldex Therapeutics | 198 |
| Disc Medicine | 165 |
| Pharvaris | 148 |
| Aurinia Pharmaceuticals | 128 |
ADMA News
- 16 hours ago - ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process - GlobeNewsWire
- 4 weeks ago - Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA) - Newsfile Corp
- 5 weeks ago - Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) - PRNewsWire
- 2 months ago - Adma Biologics reports Q2 EPS 16c, consensus 16c - TheFly
- 2 months ago - Adma Biologics backs FY26 revenue view $530M-$560M, consensus $534.37M - TheFly
- 2 months ago - ADMA Biologics Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - ADMA Biologics Earnings release: Q2 2026 - Filings
- 2 months ago - ADMA Biologics Quarterly report: Q2 2026 - Filings